| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 17 | 2023 | 111 | 6.910 |
Why?
|
| Prostatic Neoplasms | 27 | 2021 | 471 | 4.330 |
Why?
|
| Hematopoietic Stem Cells | 16 | 2019 | 100 | 3.720 |
Why?
|
| Stem Cell Niche | 11 | 2019 | 27 | 3.520 |
Why?
|
| Bone Marrow | 12 | 2020 | 70 | 2.800 |
Why?
|
| Bone Marrow Cells | 14 | 2020 | 123 | 2.680 |
Why?
|
| Osteoblasts | 16 | 2018 | 45 | 2.330 |
Why?
|
| Neoplasm Metastasis | 18 | 2021 | 220 | 1.860 |
Why?
|
| Erythropoietin | 5 | 2015 | 30 | 1.510 |
Why?
|
| Cell Proliferation | 13 | 2018 | 604 | 1.400 |
Why?
|
| Bone and Bones | 5 | 2019 | 94 | 1.340 |
Why?
|
| Cell Line, Tumor | 23 | 2020 | 726 | 1.170 |
Why?
|
| Neoplastic Stem Cells | 5 | 2016 | 99 | 1.130 |
Why?
|
| Animals | 43 | 2022 | 7541 | 1.100 |
Why?
|
| Mice | 33 | 2021 | 2484 | 1.060 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 608 | 1.010 |
Why?
|
| Humans | 67 | 2023 | 32005 | 0.990 |
Why?
|
| Flow Cytometry | 8 | 2019 | 185 | 0.970 |
Why?
|
| Mice, SCID | 14 | 2019 | 71 | 0.970 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2013 | 23 | 0.900 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2013 | 105 | 0.880 |
Why?
|
| Immunotherapy | 1 | 2023 | 81 | 0.830 |
Why?
|
| Annexin A2 | 6 | 2014 | 7 | 0.800 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2022 | 31 | 0.790 |
Why?
|
| Hematopoiesis | 3 | 2012 | 33 | 0.780 |
Why?
|
| Alpha Particles | 1 | 2021 | 7 | 0.770 |
Why?
|
| Male | 43 | 2021 | 19165 | 0.750 |
Why?
|
| Drug Delivery Systems | 1 | 2022 | 104 | 0.750 |
Why?
|
| Mesenchymal Stem Cells | 3 | 2018 | 182 | 0.740 |
Why?
|
| Osteoclasts | 7 | 2021 | 22 | 0.730 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 93 | 0.730 |
Why?
|
| Bone Marrow Transplantation | 2 | 2019 | 63 | 0.730 |
Why?
|
| Neoplasms | 3 | 2018 | 726 | 0.720 |
Why?
|
| Endothelial Cells | 3 | 2018 | 189 | 0.720 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 5 | 2016 | 18 | 0.700 |
Why?
|
| Signal Transduction | 10 | 2019 | 682 | 0.700 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 94 | 0.690 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 115 | 0.660 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2009 | 8 | 0.660 |
Why?
|
| Osteogenesis | 5 | 2012 | 82 | 0.660 |
Why?
|
| Receptors, Erythropoietin | 3 | 2015 | 4 | 0.620 |
Why?
|
| Dependovirus | 1 | 2017 | 18 | 0.600 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2016 | 85 | 0.590 |
Why?
|
| Gene Transfer Techniques | 1 | 2017 | 63 | 0.590 |
Why?
|
| Sensory Receptor Cells | 1 | 2017 | 30 | 0.590 |
Why?
|
| Bone Marrow Neoplasms | 3 | 2012 | 5 | 0.590 |
Why?
|
| Genetic Vectors | 1 | 2017 | 120 | 0.580 |
Why?
|
| Cell Differentiation | 8 | 2014 | 469 | 0.570 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 1022 | 0.560 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 308 | 0.530 |
Why?
|
| Bone Resorption | 1 | 2015 | 12 | 0.500 |
Why?
|
| Activated-Leukocyte Cell Adhesion Molecule | 1 | 2014 | 2 | 0.480 |
Why?
|
| Chemokine CXCL12 | 6 | 2014 | 25 | 0.470 |
Why?
|
| Fluorescent Dyes | 1 | 2014 | 48 | 0.460 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2013 | 9 | 0.450 |
Why?
|
| Receptors, Peptide | 2 | 2012 | 6 | 0.430 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2013 | 458 | 0.420 |
Why?
|
| Antigens, CD34 | 3 | 2008 | 57 | 0.410 |
Why?
|
| Prognosis | 7 | 2023 | 1497 | 0.370 |
Why?
|
| Neoplasm Invasiveness | 2 | 2011 | 190 | 0.350 |
Why?
|
| Cell Movement | 5 | 2016 | 169 | 0.340 |
Why?
|
| Coculture Techniques | 8 | 2012 | 81 | 0.340 |
Why?
|
| Stromal Cells | 8 | 2012 | 84 | 0.340 |
Why?
|
| Exosomes | 2 | 2021 | 43 | 0.340 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2009 | 46 | 0.340 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 148 | 0.330 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 147 | 0.330 |
Why?
|
| Cell Physiological Phenomena | 1 | 2008 | 3 | 0.320 |
Why?
|
| Urolithiasis | 1 | 2008 | 7 | 0.320 |
Why?
|
| Models, Biological | 6 | 2013 | 392 | 0.310 |
Why?
|
| Apoptosis | 4 | 2013 | 360 | 0.300 |
Why?
|
| MicroRNAs | 2 | 2021 | 180 | 0.300 |
Why?
|
| Mice, Nude | 5 | 2021 | 291 | 0.290 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 638 | 0.290 |
Why?
|
| Mice, Inbred C57BL | 7 | 2016 | 767 | 0.290 |
Why?
|
| Multiple Myeloma | 2 | 2020 | 20 | 0.280 |
Why?
|
| Phenotype | 5 | 2020 | 632 | 0.280 |
Why?
|
| Immunohistochemistry | 5 | 2013 | 538 | 0.270 |
Why?
|
| Breast Neoplasms | 4 | 2021 | 765 | 0.270 |
Why?
|
| Lymphoma, B-Cell | 1 | 2005 | 11 | 0.260 |
Why?
|
| Sarcoma, Myeloid | 1 | 2005 | 3 | 0.260 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2005 | 12 | 0.260 |
Why?
|
| Neoplasm Transplantation | 4 | 2016 | 73 | 0.250 |
Why?
|
| B-Lymphocytes | 4 | 2020 | 74 | 0.240 |
Why?
|
| Blotting, Western | 4 | 2013 | 289 | 0.240 |
Why?
|
| Myelopoiesis | 1 | 2004 | 2 | 0.240 |
Why?
|
| Down Syndrome | 1 | 2004 | 14 | 0.230 |
Why?
|
| Liver Failure | 1 | 2004 | 20 | 0.230 |
Why?
|
| Skull | 3 | 2014 | 48 | 0.230 |
Why?
|
| Mice, Inbred BALB C | 3 | 2020 | 167 | 0.230 |
Why?
|
| Female | 16 | 2021 | 19959 | 0.220 |
Why?
|
| Embryonic Stem Cells | 2 | 2014 | 28 | 0.220 |
Why?
|
| Cell Separation | 3 | 2014 | 92 | 0.220 |
Why?
|
| Ultrasonography | 2 | 2020 | 379 | 0.210 |
Why?
|
| Multipotent Stem Cells | 2 | 2014 | 17 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 261 | 0.210 |
Why?
|
| Blast Crisis | 1 | 2021 | 3 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 3 | 2019 | 170 | 0.190 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2021 | 18 | 0.190 |
Why?
|
| Cytokines | 1 | 2023 | 256 | 0.190 |
Why?
|
| Mutation | 5 | 2021 | 489 | 0.190 |
Why?
|
| Ligands | 1 | 2021 | 81 | 0.190 |
Why?
|
| DNA Methylation | 2 | 2019 | 141 | 0.190 |
Why?
|
| Prostate-Specific Antigen | 1 | 2021 | 61 | 0.190 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2019 | 67 | 0.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 14 | 0.180 |
Why?
|
| Genomic Instability | 1 | 2020 | 6 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2020 | 7 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2020 | 24 | 0.180 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 11 | 0.180 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 44 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 82 | 0.180 |
Why?
|
| Antigens, CD | 4 | 2013 | 103 | 0.180 |
Why?
|
| Primary Myelofibrosis | 1 | 2020 | 7 | 0.180 |
Why?
|
| Microglia | 1 | 2020 | 57 | 0.180 |
Why?
|
| Tibial Nerve | 1 | 2020 | 22 | 0.180 |
Why?
|
| Immunity, Innate | 1 | 2020 | 75 | 0.170 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 9 | 0.170 |
Why?
|
| Child | 5 | 2020 | 2438 | 0.170 |
Why?
|
| Sural Nerve | 1 | 2020 | 28 | 0.170 |
Why?
|
| Colitis, Ulcerative | 1 | 2019 | 23 | 0.170 |
Why?
|
| Taxoids | 1 | 2020 | 59 | 0.170 |
Why?
|
| Median Nerve | 1 | 2020 | 51 | 0.170 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2020 | 51 | 0.170 |
Why?
|
| Luminescent Measurements | 1 | 2019 | 16 | 0.160 |
Why?
|
| Luciferases | 1 | 2019 | 32 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 104 | 0.160 |
Why?
|
| X-Ray Microtomography | 1 | 2019 | 41 | 0.160 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2018 | 6 | 0.160 |
Why?
|
| Thrombospondin 1 | 1 | 2018 | 7 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 201 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 412 | 0.150 |
Why?
|
| Nicotine | 1 | 2020 | 171 | 0.150 |
Why?
|
| Green Fluorescent Proteins | 1 | 2017 | 71 | 0.150 |
Why?
|
| Bone Development | 3 | 2012 | 8 | 0.150 |
Why?
|
| Treatment Outcome | 2 | 2023 | 3306 | 0.150 |
Why?
|
| Cell Adhesion | 4 | 2012 | 108 | 0.150 |
Why?
|
| Ganglia, Spinal | 1 | 2017 | 65 | 0.140 |
Why?
|
| Spinal Cord | 1 | 2017 | 130 | 0.140 |
Why?
|
| Cell Lineage | 3 | 2014 | 71 | 0.140 |
Why?
|
| Transplantation, Heterologous | 3 | 2012 | 122 | 0.140 |
Why?
|
| Osteonectin | 1 | 2016 | 17 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 263 | 0.130 |
Why?
|
| Bone Regeneration | 2 | 2014 | 32 | 0.130 |
Why?
|
| Child, Preschool | 2 | 2013 | 1269 | 0.130 |
Why?
|
| Bone Morphogenetic Protein 2 | 2 | 2012 | 20 | 0.130 |
Why?
|
| Skin | 1 | 2017 | 211 | 0.130 |
Why?
|
| Cells, Cultured | 4 | 2014 | 833 | 0.130 |
Why?
|
| Mice, Knockout | 5 | 2021 | 443 | 0.130 |
Why?
|
| Gene Expression | 3 | 2013 | 338 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2012 | 6 | 0.120 |
Why?
|
| Chemokines | 2 | 2011 | 35 | 0.120 |
Why?
|
| Stem Cells | 3 | 2020 | 313 | 0.120 |
Why?
|
| Staining and Labeling | 1 | 2014 | 60 | 0.120 |
Why?
|
| Cell Survival | 2 | 2016 | 284 | 0.110 |
Why?
|
| Research | 1 | 2014 | 74 | 0.110 |
Why?
|
| Clinical Medicine | 1 | 2013 | 12 | 0.110 |
Why?
|
| Tissue Array Analysis | 2 | 2012 | 34 | 0.110 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2013 | 50 | 0.110 |
Why?
|
| Animals, Newborn | 2 | 2010 | 114 | 0.110 |
Why?
|
| Bone Morphogenetic Proteins | 2 | 2010 | 23 | 0.110 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2020 | 84 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 104 | 0.110 |
Why?
|
| Chemotaxis | 2 | 2009 | 24 | 0.110 |
Why?
|
| Pluripotent Stem Cells | 1 | 2012 | 18 | 0.110 |
Why?
|
| Receptors, CXCR | 2 | 2013 | 3 | 0.100 |
Why?
|
| Myeloid Cells | 2 | 2012 | 39 | 0.100 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 25 | 0.100 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 209 | 0.090 |
Why?
|
| Quality of Life | 1 | 2016 | 946 | 0.090 |
Why?
|
| Infant | 1 | 2013 | 1061 | 0.090 |
Why?
|
| Age Factors | 1 | 2013 | 1188 | 0.090 |
Why?
|
| Phosphoglycerate Kinase | 1 | 2009 | 2 | 0.090 |
Why?
|
| Culture Media, Conditioned | 1 | 2009 | 51 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 153 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2011 | 198 | 0.090 |
Why?
|
| Tissue Engineering | 1 | 2015 | 656 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2005 | 1328 | 0.080 |
Why?
|
| Interleukin-3 | 1 | 2008 | 11 | 0.080 |
Why?
|
| Stem Cell Factor | 1 | 2008 | 13 | 0.080 |
Why?
|
| Carcinoma | 1 | 2009 | 91 | 0.080 |
Why?
|
| Hepatomegaly | 1 | 2008 | 2 | 0.080 |
Why?
|
| Splenomegaly | 1 | 2008 | 7 | 0.080 |
Why?
|
| Lymphatic Diseases | 1 | 2008 | 10 | 0.080 |
Why?
|
| Gingival Crevicular Fluid | 1 | 2008 | 1 | 0.080 |
Why?
|
| Alveolar Bone Loss | 1 | 2008 | 3 | 0.080 |
Why?
|
| Periodontitis | 1 | 2008 | 9 | 0.080 |
Why?
|
| RNA Interference | 3 | 2013 | 76 | 0.080 |
Why?
|
| Interleukin-7 | 1 | 2007 | 10 | 0.070 |
Why?
|
| Adult | 5 | 2021 | 9345 | 0.070 |
Why?
|
| Middle Aged | 5 | 2021 | 11817 | 0.070 |
Why?
|
| Antigens, Differentiation | 2 | 2020 | 25 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2008 | 256 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2006 | 8 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2021 | 1817 | 0.070 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2005 | 1 | 0.070 |
Why?
|
| Immunocompetence | 1 | 2005 | 11 | 0.070 |
Why?
|
| Protein Binding | 3 | 2012 | 201 | 0.060 |
Why?
|
| Peroxidase | 1 | 2005 | 31 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 43 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2013 | 3509 | 0.060 |
Why?
|
| Flavonoids | 1 | 2005 | 18 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 77 | 0.060 |
Why?
|
| Leukemia | 1 | 2005 | 40 | 0.060 |
Why?
|
| Type C Phospholipases | 1 | 2004 | 7 | 0.060 |
Why?
|
| Aged | 4 | 2021 | 10301 | 0.060 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2004 | 3 | 0.060 |
Why?
|
| Procollagen | 1 | 2004 | 7 | 0.060 |
Why?
|
| Collagen Type IV | 1 | 2004 | 8 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2004 | 49 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2020 | 2282 | 0.060 |
Why?
|
| Fetal Diseases | 1 | 2004 | 19 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 101 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2004 | 83 | 0.060 |
Why?
|
| Hyaluronic Acid | 1 | 2004 | 52 | 0.060 |
Why?
|
| Cell Line | 3 | 2012 | 435 | 0.060 |
Why?
|
| Liver Cirrhosis | 1 | 2004 | 81 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2004 | 136 | 0.060 |
Why?
|
| Mitochondria | 1 | 2005 | 187 | 0.050 |
Why?
|
| Sirolimus | 2 | 2013 | 33 | 0.050 |
Why?
|
| Glycoproteins | 2 | 2013 | 45 | 0.050 |
Why?
|
| Calcium | 1 | 2004 | 307 | 0.050 |
Why?
|
| Diet | 1 | 2005 | 391 | 0.050 |
Why?
|
| Peptides | 2 | 2013 | 120 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2004 | 671 | 0.050 |
Why?
|
| Proto-Oncogene Protein c-ets-2 | 1 | 2021 | 2 | 0.050 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2021 | 2 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 8 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 16 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2021 | 19 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 40 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2021 | 113 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2004 | 399 | 0.050 |
Why?
|
| Receptors, CXCR4 | 2 | 2013 | 11 | 0.050 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 8 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 85 | 0.050 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2020 | 27 | 0.050 |
Why?
|
| Chemokine CCL20 | 1 | 2020 | 6 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 13 | 0.050 |
Why?
|
| Pregnancy | 1 | 2004 | 997 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 21 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2020 | 20 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 72 | 0.050 |
Why?
|
| Japan | 1 | 2020 | 17 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2020 | 13 | 0.050 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2020 | 2 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2020 | 220 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 14 | 0.040 |
Why?
|
| Ankle | 1 | 2020 | 29 | 0.040 |
Why?
|
| Epidermis | 1 | 2020 | 30 | 0.040 |
Why?
|
| Albumins | 1 | 2020 | 45 | 0.040 |
Why?
|
| Electrodiagnosis | 1 | 2020 | 42 | 0.040 |
Why?
|
| Forearm | 1 | 2020 | 43 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2020 | 37 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 67 | 0.040 |
Why?
|
| Wrist | 1 | 2020 | 48 | 0.040 |
Why?
|
| Alleles | 1 | 2020 | 248 | 0.040 |
Why?
|
| Leg | 1 | 2020 | 65 | 0.040 |
Why?
|
| Neural Conduction | 1 | 2020 | 91 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 483 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 545 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2012 | 229 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 3990 | 0.040 |
Why?
|
| Adolescent | 2 | 2021 | 3539 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 215 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2016 | 1 | 0.040 |
Why?
|
| Histones | 1 | 2016 | 53 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 61 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2016 | 18 | 0.030 |
Why?
|
| Azacitidine | 1 | 2016 | 28 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 77 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 36 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 55 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 208 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2016 | 181 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1531 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2265 | 0.030 |
Why?
|
| Cell Size | 1 | 2014 | 38 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 2636 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 367 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2013 | 8 | 0.030 |
Why?
|
| Chondrocytes | 1 | 2014 | 74 | 0.030 |
Why?
|
| Adipocytes | 1 | 2014 | 81 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 29 | 0.030 |
Why?
|
| Chemokine CXCL6 | 1 | 2013 | 1 | 0.030 |
Why?
|
| Receptors, Scavenger | 1 | 2013 | 7 | 0.030 |
Why?
|
| Chemokines, CXC | 1 | 2013 | 9 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2013 | 14 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 114 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 2013 | 9 | 0.030 |
Why?
|
| Blood Component Removal | 1 | 2012 | 4 | 0.030 |
Why?
|
| Antimutagenic Agents | 1 | 2012 | 1 | 0.030 |
Why?
|
| Cobalt | 1 | 2012 | 5 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2013 | 111 | 0.030 |
Why?
|
| Cadherins | 1 | 2012 | 26 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 25 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2012 | 58 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 23 | 0.030 |
Why?
|
| Osteolysis | 1 | 2012 | 7 | 0.030 |
Why?
|
| Cathepsin K | 1 | 2012 | 2 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 18 | 0.030 |
Why?
|
| NFATC Transcription Factors | 1 | 2012 | 5 | 0.030 |
Why?
|
| Calcification, Physiologic | 1 | 2012 | 8 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 41 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 36 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 43 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 70 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 142 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2012 | 83 | 0.020 |
Why?
|
| Antimetabolites | 1 | 2010 | 11 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 594 | 0.020 |
Why?
|
| Biological Assay | 1 | 2010 | 19 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2012 | 247 | 0.020 |
Why?
|
| Cell Transplantation | 1 | 2010 | 64 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 81 | 0.020 |
Why?
|
| Neurons | 1 | 2014 | 410 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 264 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2011 | 245 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 8 | 0.020 |
Why?
|
| Periodontal Index | 1 | 2008 | 6 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2008 | 20 | 0.020 |
Why?
|
| Mesoderm | 1 | 2008 | 14 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 52 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 130 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2008 | 45 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 495 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 91 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 198 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 246 | 0.020 |
Why?
|
| Neutrophils | 1 | 2008 | 106 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2008 | 70 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 252 | 0.020 |
Why?
|
| DNA | 1 | 2008 | 226 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 743 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 898 | 0.020 |
Why?
|
| Graft Survival | 1 | 2007 | 313 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2005 | 8 | 0.020 |
Why?
|
| Caspases | 1 | 2005 | 39 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2005 | 50 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2005 | 81 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2005 | 135 | 0.020 |
Why?
|
| Pre-B Cell Receptors | 1 | 2004 | 1 | 0.020 |
Why?
|
| Phospholipase C gamma | 1 | 2004 | 6 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2004 | 11 | 0.020 |
Why?
|
| Rats | 1 | 2008 | 1595 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 633 | 0.010 |
Why?
|
| Aging | 1 | 2008 | 946 | 0.010 |
Why?
|